newsfilter
← Latest News
Earnings Call Transcripts·

MAXCYTE, INC. STEPHENS ANNUAL INVESTMENT CONFERENCE | NASH2026 - MAXCYTE INC

  • Financial Performance:

    • Q3 earnings saw revenue growth of 27% for core revenue; PA (Professional Services/Consumables) revenue grew 20%, with instruments and licenses performing in the mid-to-high single digits.
    • Net losses decreased by nearly 50% year-over-year due to improved operating leverage and tight control over operating expenses.
    • Cash burn for legacy MaxSight is projected to exit the current year at $17 million, dropping to less than $10 million in 2027 following the Akron acquisition and integration synergies.
    • The combined company targets a low 70s gross margin profile (MaxSight high 70s + Akron mid 60s) with $3–4 million in expected cost synergies.
    • MaxSight currently expects to generate $34.5 million in total revenue for the year, having raised guidance previously.
    • Cash reserves are projected to be $40–45 million post-closing, providing a runway to reach cash flow positivity by the end of 2027.
  • Guidance and Future Outlook:

    • Management anticipates returning to growth in the second half of the previous year's period, a trend expected to continue through 2027–2029.
    • Long-term goal is to achieve cash flow positivity, with management stating they are "in spitting distance" by the end of 2027.
    • Revenue growth is expected to be driven by the commercialization of cell therapies, with potential for 8–9 commercial programs in the combined portfolio by late 2027/early 2028.
    • Revenue synergies are projected to be minimal in 2027, with uptake beginning in 2028 and accelerating in 2029 as cross-selling to European and Asia-Pacific markets occurs.
    • Management expects to sign one multi-platform large pharma license agreement annually, though sales cycles are long (approx. 24 months).
  • Business Segments and Product Lines:

    • MaxSight (Electroporation): Core platform offers seamless workflows from research (DTX system) to clinical/commercial (GTX system); currently supports 13 clinical programs and one approved commercial product (Casgevy).
    • Akron Acquisition: Doubles annual revenue, adding a leading growth factor and reagent platform; brings proprietary liquid cytokines/growth factors stable for 12+ months at refrigerated temperatures in closed, bio-welded systems.
    • Secure: Provides off-target safety assessment services; revenue growth has been slower than anticipated but steady, with potential for acceleration through Akron's distribution.
    • Product Expansion: The combined entity now covers the entire cell therapy workflow (non-viral, viral, expansion, activation) and supports 770+ programs (up from ~50%).
    • Revenue Model Shift: Royalties from commercial products (e.g., Casgevy) will be reported as core recurring revenue; milestones remain non-recurring. Casgevy royalties contributed $1M in Q3 with significant ramp-up potential as sales scale.
  • Market and Competitive Landscape:

    • Market funding has stabilized at ~$3.5 billion in 2025 (up 19% from 2024), shifting toward late-stage programs (e.g., Phase 3) rather than early-stage biotechs.
    • Market trend shows a shift toward solid tumors (40–45% of indications), whereas historically the space was dominated by blood cancers; ex-vivo programs remain ~40% of the clinical pipeline.
    • Akron differentiates from competitors like Sartorius and Thermo Fisher via unique liquid cytokine formulations in closed systems that enable automation and reduce manufacturing costs.
    • The company is transitioning from a niche electroporation player to a broad cell therapy solutions provider, now embedded in 5 commercial therapies with 4 more in Phase 3 (via Akron).
  • Risks and Challenges:

    • Early-stage biotech funding remains constrained, creating pockets of weakness for early research-stage customers, though academic clinical trials are expanding.
    • Sales cycles for large pharma multi-platform licenses are lengthy (24+ months) compared to the biotech SPL model.
    • Regulatory and manufacturing "stickiness" presents a challenge: once products are specified into clinical programs, switching suppliers is difficult, but gaining that initial specification requires early engagement.
    • Secure's adoption rate is slow as many companies prefer to perform safety assays in-house rather than outsourcing.
  • Management Commentary and Tone:

    • Tone is highly confident and optimistic, emphasizing the strategic fit of the Akron acquisition and the maturity of the combined organization.
    • CEO Mahir Masood highlighted the successful execution of cost efficiencies and the transition to a "self-help provider" embedded in the commercial workflow.
    • CFO Parmeet Ahuja emphasized strong operating leverage, noting the reduction in cash burn from historical levels of $50M+ to current levels, and the path to cash flow positivity.
    • Management expressed excitement about the "win-win" synergy, noting they were not the highest bidder but the best strategic fit for Akron's global expansion.
  • Analyst Questions and Answers:

    • Q: Strategic focus post-acquisition? A: Expansion into the full cell therapy workflow (viral and non-viral), embedding into 5 commercial therapies, and leveraging MaxSight's global sales team to expand Akron's US-centric presence to Europe and APAC.
    • Q: Revenue synergies timing? A: Minimal in 2027 (lead exchange); revenue synergies expected to materialize significantly in 2028–2029 due to the long customer lifecycle.
    • Q: Cost synergies? A: Targeting $3–4M in 2027 from corporate consolidation; further efficiency opportunities expected in 2028.
    • Q: Market headwinds? A: Funding has shifted to late-stage programs; early-stage funding is harder to secure, but the company is seeing growth in academic trials and late-stage funding (e.g., Alatera).
    • Q: Genentech partnership impact? A: Provides a stable, large pharma model complementing the biotech SPL model; contributed a bolus of instrument sales in Q3, with recurring consumable revenue to follow in 2027.
    • Q: M&A strategy? A: No immediate new M&A; focus is on integrating Akron and executing on organic growth. Future M&A may be considered for specific tech additions but is not the current priority.
  • Other Key Points:

    • Akron's leadership team (Ezekiel Zillerberg, Dave Smith) remains in place to lead operations and commercialization post-closing.
    • The combined entity now supports "non-viral" and "viral" workflows, moving beyond MaxSight's original non-viral focus.
    • MaxSight's SPL (Success and Progress) model, which includes royalties and milestones, is becoming a significant recurring revenue stream, particularly with Casgevy.
    • Management noted that the acquisition positions the company to benefit from the anticipated approval of 2–3 more commercial cell therapies in the early 2028 timeframe.
Company
MAXCYTE INC
Keywords
MAXCYTE INC